Search
Diiodohydroxyquinoline
go.drugbank.com/drugs/DB09115ApprovedDiiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.
Mixtures: Alcortin A, Alcortin AEtynodiol
go.drugbank.com/drugs/DB13866ExperimentalWhile etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol. … Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed.
Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase
go.drugbank.com/drugs/DB18681ExperimentalAutologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy. … It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.
Sulfaisodimidine
go.drugbank.com/drugs/DB13283ExperimentalSulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been
Gonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedIt is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalPanitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions.
XL765
go.drugbank.com/drugs/DB05241InvestigationalIt is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).
Ibuzatrelvir
go.drugbank.com/drugs/DB19451InvestigationalAre at Risk for Severe Disease). … Ibuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.